Angelica Welch

Articles

CAR T-Cell Therapy Brings Hope to Relapsed/Refractory Myeloma

September 20th 2018

Eric Smith, MD, PhD, discusses the development of novel CAR T-cell therapies for patients with multiple myeloma.

Diagnosis of ITP Remains a Challenge for Clinicians

September 20th 2018

Ronald S. Go, MD, discusses the current treatment strategies of patients with ITP, as well as the process that some physicians use to determine whether a patient is suffering from the disorder.

Immunotherapy Could Still Have Pivotal Role in Ovarian Cancer

September 19th 2018

Matthew Powell, MD, discusses the promise of immunotherapy in ovarian cancer despite its challenges.

Novel Ruxolitinib Approaches Explored in Myelofibrosis

September 17th 2018

Researchers are exploring combination approaches with ruxolitinib (Jakafi) in myelofibrosis as a potential strategy for reinvigorating the drug’s effect in patients who progress, relapse, or become intolerant on single-agent treatment with the JAK inhibitor.

Expert Predicts Promising Regimens Ahead in MCL

September 16th 2018

The pipeline for relapsed/refractory mantle cell lymphoma treatment is beginning to evolve with novel agents and combination regimens that have the potential to improve patient outcomes.

Asymptomatic, Young Patients With MCL May Avoid Active Treatment

September 15th 2018

Frontline therapy may be able to be avoided in asymptomatic, young, fit patients with mantle cell lymphoma.

Carfilzomib Combos Deemed Safe in Multiple Myeloma

September 15th 2018

Updated safety data of the ASPIRE and ENDEAVOR trials showed that carfilzomib-based (Kyprolis) regimens demonstrate benefit across patient populations of multiple myeloma.

Role of CAR T-Cell Therapy in Pediatric ALL Continues to Be Refined

September 14th 2018

While clinical trial findings with chimeric antigen receptor (CAR) T-cell therapy have impacted the landscape of pediatric acute lymphoblastic leukemia, additional CAR T-cell products continue to be investigated.

Recognizing Predisposition Syndromes Can Impact Pediatric MDS and AML Treatment

September 14th 2018

Early identification of inherited predisposition to forms of myelodysplastic syndrome and acute myeloid leukemia in pediatric patients can assist in treatment decisions and selection for familial stem cell transplant.

Novel Agents Lead Charge Against Adult ALL

September 13th 2018

Julio C. Chavez, MD, discusses prognostic indicators and systemic treatment updates for patients with acute lymphoblastic leukemia.

Hall Addresses Selection for Chemoimmunotherapy in NSCLC

September 11th 2018

Richard D. Hall, MD, recaps updates from the 2018 AACR Annual Meeting and the 2018 ASCO Annual Meeting in non–small cell lung cancer.

Expert Emphasizes Importance of Collaboration for Rare Pediatric Cancers

September 10th 2018

Matthew Ladra, MD, MPH, discusses the treatment of patients with esthesioneuroblastoma, emphasizing the need for collaboration in this rare malignancy.

Immunotherapy Inches Into SCLC Landscape

September 8th 2018

Josephine L. Feliciano, MD, discusses the role of immunotherapy and the potential of targeted agents in small cell lung cancer.

Expert Addresses Global Cervical Cancer Disparity

September 7th 2018

Ophira Ginsburg, MD, discusses cervical cancer prevention, screening, and elimination on a global scale.

Study Evaluates Risk of Breast Cancer for Childhood Survivors of Cancer

September 7th 2018

Zhaoming Wang, PhD, discusses the first assessment of the joint effects of rare and common genetic variations in survivors of childhood cancers.

Frontline Quizartinib Is Tested in AML Subgroup

September 6th 2018

Quizartinib, a small molecule receptor tyrosine kinase inhibitor targeting FLT3, is currently being evaluated in combination with chemotherapy in patients with newly diagnosed FLT3-ITD–positive AML.

PARP/Immunotherapy Combo Shows Promise in Recurrent Ovarian Cancer

September 5th 2018

Panagiotis A. Konstantinopoulos, MD, PhD, discusses the findings of the TOPACIO/KEYNOTE-162 study and the future for PARP inhibitor combinations and immunotherapy overall in ovarian cancer.

A Legacy of Hope for Young Leukemia Patients

September 3rd 2018

Joseph V. Simone, MD, is best known for leading the research efforts that resulted in the first curative combination treatment for certain pediatric patients with acute lymphoid leukemia. Under his leadership, the St. Jude Children’s Research Hospital in Memphis, Tennessee, was designated the first and only National Cancer Institute cancer center dedicated to children. He was honored in the Pediatric Oncology category with a 2017 Giants of Cancer Care® award.

Cemiplimab Offers Hope in Metastatic CSCC

August 31st 2018

Danny Rischin, MD, MBBS, FRACP, discusses the potential for cemiplimab as a novel PD-1 inhibitor for patients with metastatic and locally advanced cutaneous squamous cell carcinoma.

Expert Outlines Clinical Implications of Precision Medicine in GI Cancers

August 31st 2018

Shirley Michelle Shiller, DO, discusses the clinical application of precision medicine in gastrointestinal cancer.